Pharma BD Deal Intelligence
The $2.4B acquisition that bought BMS the intellectual property behind the immuno-oncology revolution. Medarex's UltiMAb platform generated nivolumab (Opdivo) and ipilimumab (Yervoy), creating a franchise exceeding $10B in peak annual sales.
BMS / Medarex: Achieved Stated Rationale (Score: 96/100)
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS acquired Medarex for $2.4B as part of String of Pearls strategy.
BMS / Medarex: Achieved Stated Rationale (Score: 96/100)
Assessment window: 10yr post-close.
68K US cases/yr · $1.5B US Melanoma Therapeutics Market (2009)
The BMS-Medarex acquisition for $2.4B was a defining moment in immuno-oncology. Ipilimumab (Yervoy), a CTLA-4 checkpoint inhibitor in Phase III for melanoma, plus the UltiMAb human antibody platform and ADC technology. Ipilimumab became the first checkpoint inhibitor approved (March 2011).
Yervoy was approved for melanoma in March 2011, the first drug to improve overall survival in metastatic melanoma. Peak sales ~$1.5B. The UltiMAb platform contributed to the broader IO revolution. Combined with nivolumab (from Ono), BMS built the leading IO franchise.
Bristol-Myers Squibb Co. closes acquisition/merger of Medarex Inc. for $2.4B, establishing strategic position and initiating integration.
Strategic Fit: 95/100 | Financial Return: 98/100 | Pipeline Outcome: 98/100 | Integration: 90/100 | Deal Difficulty: 50/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Medarex Inc. (this deal) | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2009 deals · Bristol-Myers Squibb Company deals · Oncology deals